Dear Fabry Community,
During this challenging time with the global COVID-19 outbreak, it is all the more important we look out for and support one another. The safety and welfare of families affected by rare diseases always has been and continues to be Amicus’ number one priority. Our commitment to the rare disease community will continue and we are only a phone call or email away. For questions or support, we can be reached at firstname.lastname@example.org or toll-free in the US at 1(866) 9-AMICUS (926-4287).
Sodi A, Ioannidis A, Pitz S. Ophthalmological manifestations of Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G, eds. Fabry Disease: Perspectives from s Years of FOS. Oxford, England: Oxford Pharma Genesis; 2006: Chapter 26. https://www.ncbi.nlm.nih.gov/books/NBK11599. Accessed August 16, 2019.
Cole AL, Lee PJ, Hughes DA, Deegan PB, Waldek S, Lachmann RH. Depression in adults with Fabry disease: a common and under-diagnosed problem. J Inherit Metab Dis. 2007;30(6):943-951.
Bolsover FE, Murphy E, Cipolotti L, Werring DJ, Lachmann RH. Cognitive dysfunction and depression in Fabry disease: a systematic review. J Inherit Metab Dis. 2014;37(2):177-187.
Aubert JD, Barbey F. Pulmonary involvement in Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G, eds. Fabry Disease: Perspectives from s Years of FOS. Oxford, England: Oxford Pharma Genesis; 2006: Chapter 27. https://www.ncbi.nlm.nih.gov/books/NBK11589. Accessed August 16, 2019.
Franzen D, Gerard N, Bratton DJ, et al. Prevalence and risk factors of sleep disordered breathing in Fabry disease: A prospective cohort study. Medicine. 2015;94(52):1-6.
You are now leaving the FabryFacts.com website
You are now leaving the FabryFacts.com website. This link will take you to a site that is owned by Amicus Therapeutics.